Recombinant rift valley fever (RVF) viruses and methods of use
AssigneeThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
InventorsBrian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
Life of this patent
Estimating the term…
Abstract
Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.
Claims7
A method of differentiating vaccination with a recombinant Rift Valley fever (RVF) virus from a natural RVF virus infection in a subject, wherein the genome of the recombinant RVF virus comprises (i) a full-length L segment;
- (ii) a full-length M segment or an M segment comprising a complete deletion of the NSm open reading frame (ORF);
- and (iii) an S segment comprising a complete deletion of the NSs ORF, the method comprising:
- obtaining a body fluid sample from the subject;
- and
- detecting the presence of anti-NP antibodies and the absence of anti-NSs antibodies in the sample, thereby determining that the subject was vaccinated with the recombinant RVF virus;
- or detecting the presence of both anti-NP and anti-NSs antibodies in the sample, thereby determining that the subject was naturally infected with RVF virus.
Dependencies are inferred from the claim text.